Brief: Ovid Therapeutics Q2 EPS USD 0.12 Vs. IBES Estimate USD -0.22
13/08/2024 13:00
Aug 13 (Reuters) - Ovid Therapeutics Q2 basic EPS USD 0.12. * Q2 net income USD 8.521 million * Q2 operating expenses USD 20.686 million
Recent news on Ovid Therapeutics
See all newsOvid Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Ovid Therapeutics Q2 revenue beats estimates
Brief: Ovid Therapeutics Q2 EPS USD -0.08
Ovid Therapeutics Inc. expected to post a loss of 11 cents a share - Earnings Preview
Brief: Ovid Therapeutics Appoints Leading Physician-Scientist And Biotech Innovator Anna Greka, M.D., Ph.D., To Board Of Directors